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had higher body mass index levels (31 kg/m2 vs. 27 kg/m2; 
p < 0.01) and lower cardiac troponin I (9 pg/ml vs. 15 pg/
ml; p = 0.02). In addition, these patients were less frequently 
prescribed diuretics and beta-blockers. No differences in 
quality of life, heart failure related symptoms and the pri-
mary and secondary outcomes were observed between these 
groups. These observations were confirmed for NT-proBNP.
Conclusion Among the patients with clinically diagnosed 
HFpEF, those with low BNP are strikingly similar to those 
with elevated BNP levels, except for BMI, which was sig-
nificantly higher in these patients.
Keywords Heart failure · Preserved ejection fraction · 
Quality of life · B-type Natriuretic peptide · Biomarkers · 
Symptoms
Introduction
Heart failure with preserved ejection fraction (HFpEF) is a 
prevalent cause of cardiovascular morbidity and mortality 
[1] and the incidence is still increasing [2]. Patients with 
either HFpEF or heart failure with reduced ejection fraction 
(HFrEF) are generally comparable regarding signs, symp-
toms and quality of life (QoL) [3]. But HFpEF patients 
are more often elderly, female and more frequently have 
hypertension, atrial fibrillation and other comorbidities [4], 
whereas HFrEF patients have a higher prevalence of coro-
nary artery disease and myocardial infarction [5]. Due to the 
presence of these comorbidities, often with heart failure-like 
symptoms, the diagnosis of HFpEF is difficult, and in fact 
some patients with assumed HFpEF might not have heart 
failure, but suffer from other conditions such as anaemia, 
lung disease, or depression.
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Abstract
Aims Heart failure with preserved ejection fraction (HF-
pEF) is common and its management remains difficult. B-
type natriuretic peptide (BNP) levels are used to diagnose 
heart failure, and as an entry criterion for inclusion into tri-
als. We investigated a population of HFpEF patients who 
had been randomised into a study based on clinical parame-
ters, and compared those with low BNP levels to those with 
elevated BNP levels.
Methods We examined patients who had been enrolled in 
the Coordinating study evaluating Outcomes of Advising 
and Counselling in Heart Failure (COACH), with preserved 
left ventricular ejection fraction (LVEF ≥ 40 %), and com-
pared those with low BNP (< 100 pg/ml; n = 30) to those with 
elevated BNP (≥ 100 pg/ml; n = 127). Baseline characteris-
tics, comorbidities, biomarkers, quality of life, and outcome 
parameters (hospitalisations and death) were compared be-
tween the groups. To validate our findings, we repeated all 
analyses for NT-proBNP (< 300 pg/ml and ≥ 300 pg/ml).
Results Patients were similar with regard to most clinical 
characteristics (including age, sex, and LVEF), biomark-
ers, and comorbidities. In contrast, patients with a low BNP 
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Biochemical measurements
An extensive description of the assays used can be found in 
the Online supplement.
Quality of life and heart failure symptoms
QoL measurements were collected during hospitalisation 
and were assessed in two different ways. Global well-
being was assessed by Cantril’s Ladder of Life [12] and the 
Medical Outcome Study 36-item General Health Survey 
(RAND36) assessed disease generic QoL [13]. Both estab-
lished measurements are further explained in the Online 
Supplement together with the assessment of heart failure 
symptoms.
Statistical analyses
Descriptive statistics were used to characterise the study 
population. Cox proportional hazards regression analyses 
were performed to adjust for the time to event. Kaplan-
Meier curves were constructed for the different time to event 
evaluations. We repeated our analyses for patients with low 
NT-proBNP and high NT-proBNP levels.
P-values below < 0.05 were considered to denote sig-
nificant differences. Analyses were performed with STATA 
software (version 13.0, Stata Corp, College Station, Texas, 
USA).
Results
Patient characteristics
Of the 1023 patients enrolled, 157 patients had an LVEF 
≥ 40 %, and complete data on BNP and QoL. Patients had 
a mean age of 73 (± 9), 45 % were female, and they had 
a mean LVEF of 51 % (± 9 %) and a median BNP level of 
352 pg/ml [149–791 pg/ml]. This is substantially lower 
than in the overall COACH cohort (median BNP 447 pg/
ml [195–888 pg/ml]). Of the 157 patients with an LVEF 
≥ 40 %, 30 patients (19 %) had BNP levels lower than 
100 pg/ml. Patients with low BNP levels had a higher body 
mass index (BMI; 31 kg/m2 vs. 27 kg/m2; p < 0.01) and were 
less often treated with beta-blockers and diuretics (30 % vs. 
65 %; p < 0.001 and 87 % vs. 98 %, respectively, p < 0.01) 
(Table 1). However, other important clinical characteristics 
were very comparable between the HFpEF patients with 
low or elevated BNP. Likewise, comorbidities including 
chronic obstructive pulmonary disease, diabetes and anae-
mia were equally frequent in patients with either low or high 
BNP levels. Biomarkers commonly measured in heart fail-
ure patients such as cystatin C, galectin-3, interleukin 6, and 
The guidelines of the European Society of Cardiology 
(ESC) state that for a diagnosis of heart failure, untreated 
patients with symptoms of heart failure should have at 
least B-type natriuretic peptide (BNP) levels of 100 pg/
ml to confirm a possible diagnosis of heart failure (or NT-
proBNP levels of 300 pg/ml) [6]. In a very recent meta-
analysis [7], 37 unique study cohorts with over 15,000 test 
results were available, and the proposed rule-out thresh-
old for BNP recommended by the 2012 ESC guidelines 
was shown to have excellent ability to exclude acute heart 
failure. However, no distinction could be made between 
HFpEF and HFrEF patients as data on BNP cut-off points 
in HFpEF are rare and ill-validated. Interestingly, a group 
of HFpEF patients with BNP levels below 100 do not offi-
cially meet the diagnostic criteria. This raises the question 
whether and how these patients, who are a clinical reality, 
differ from patients with HFpEF and BNP levels ≥ 100 pg/
ml.
Therefore, we compared HFpEF patients with or with-
out low BNP levels for their baseline characteristics, heart 
failure symptoms, biomarkers, QoL measurements and out-
come parameters.
Methods
Patient population
Data were collected as part of the Coordinating study evalu-
ating Outcomes of Advising and Counselling in Heart fail-
ure (COACH), as described in detail elsewhere [8, 9]. In 
brief, patients who were admitted for heart failure were 
enrolled in COACH before discharge, and randomised to 
standard of care or to nurse-led interventions. In the current 
sub-study only patients with a left ventricular ejection frac-
tion (LVEF) ≥ 40 %, with complete data on BNP and QoL 
were included, as previously described [10]. The study was 
performed in accordance with the principles outlined in the 
Declaration of Helsinki and was approved by the Medical 
Ethics Committee in each participating centre. All subjects 
provided informed consent. Further details are described in 
the Online Supplement.
Endpoints
The primary outcome was all-cause mortality and/or rehos-
pitalisation for heart failure after 18 months. Secondary 
outcomes were all-cause mortality, heart failure rehospitali-
sation, cardiovascular rehospitalisation, or all-cause rehos-
pitalisation after 18 months. We also analysed all-cause 
mortality after 36 months. An independent endpoint com-
mittee adjudicated all endpoints [11].
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Quality of life
The mean score on global well-being, as measured with 
Cantril’s Ladder of Life, did not differ significantly between 
HFpEF patients with low BNP levels and high BNP levels 
(Table 2). Also, no significant differences were observed 
between the two groups in any of the dimensions of the 
RAND36 (Table 2).
neutrophil gelatinase-associated lipocalin (NGAL) showed 
no differences between the two groups, but cardiac troponin 
I (cTnI) was significantly lower in patients with low BNP 
levels (9 pg/ml vs. 15 pg/ml; p = 0.02). BNP levels gradu-
ally decreased stratified by the World Health Organisation 
BMI classification scale (underweight < 18.5 kg/m2; nor-
mal range 18.5–25 kg/m2; overweight 25–30 kg/m2; obese 
> 30 kg/m2) (p-trend < 0.001) (Fig. 1).
Table 1 Baseline characteristics of patients with HFpEF enrolled in the COACH study: overall and stratified by BNP levels
Characteristics Total (n = 157) BNP < 100 pg/ml (n = 30) BNP ≥ 100 pg/ml (n = 127) p-value
Age (y), mean (SD) 73 (9) 72 (9) 73 (9) 0.51
Female, n (%) 71 (45) 12 (40) 59 (47) 0.52
SBP (mmHg), mean (SD) 125 (22) 125 (25) 125 (22) 0.94
DBP (mmHg), mean (SD) 69 (13) 73 (16) 68 (12) 0.04
Heart rate (bpm), mean (SD) 72 (12) 73 (13) 72 (12) 0.51
BMI (kg/m2), mean (SD) 28 (6) 31 (7) 27 (5) < 0.01
HF history
NYHA class II 88 (56) 12 (40) 76 (60) 0.10
 III 61 (39) 15 (50) 46 (36)
 IV 8 (5) 3 (10) 5 (4)
LVEF (%), mean (SD) 51 (9) 53 (10) 50 (8) 0.06
Previous MI, n (%) 51 (33) 6 (20) 45 (35) 0.10
Distance 6MWT, mean (SD) 212 (131) 169 (106) 222 (135) 0.09
Comorbidities
Asthma 6 (4) 0 (0) 6 (5) 0.22
Atrial fibrillation 79 (50) 15 (50) 64 (50) 0.97
Anaemia 43 (43) 6 (33) 37 (45) 0.38
COPD 53 (34) 11 (37) 42 (33) 0.71
Diabetes 45 (29) 8 (27) 37 (29) 0.79
Hypertension 78 (50) 16 (53) 62 (49) 0.66
Stroke 26 (17) 5 (17) 21 (17) 0.99
Treatment
ACEi/ARB, n (%) 123 (78) 25 (83) 98 (77) 0.46
b-Blocker, n (%) 92 (59) 9 (30) 83 (65) < 0.001
Loop diuretic, n (%) 151 (96) 26 (87) 125 (98) < 0.01
MRA, n (%) 67 (43) 11 (37) 56 (44) 0.46
Digoxin, n (%) 49 (31) 8 (27) 41 (32) 0.55
Laboratory measurements
Sodium (mmol/l), mean (SD) 139 (4) 138 (6) 139 (4) 0.31
Potassium (mmol/l), mean (SD) 4 (1) 4 (1) 4 (1) 0.44
Urea (mmol/l), mean (SD) 14 (8) 16 (9) 13 (8) 0.11
Creatinine (mmol/l), mean (SD) 127 (61) 129 (51) 126 (63) 0.84
eGFR (ml/min per 1.73 m2), mean (SD) 54 (21) 51 (16) 54 (22) 0.42
Biomarkers
BNP (pg/ml), median [IQR] 352 [149–791] 53 [34–72] 457 [244–864] < 0.001
Cystatin C (mg/ml), median [IQR] 11.3 [7.8–15.7] 11.2 [9.2–19.0] 11.4 [7.7–15.7] 0.84
Galectin-3 (ng/ml), median [IQR] 19 [15–25] 19 [14–27] 19 [15–25] 0.77
Interleukin 6 (ng/ml), median [IQR] 12 [7–23] 11 [6–22] 12 [7–24] 0.70
NGAL (ng/ml), median [IQR] 113 [87–165] 147 [81–181] 109 [87–147] 0.34
Troponin I (pg/ml), median [IQR] 14 [6–31] 9 [4–13] 15 [7–35] 0.02
BNP B-type natriuretic peptide, SBP systolic blood pressure, DBP diastolic blood pressure, BMI body mass index, HF heart failure, NYHA 
New York Heart Association, LVEF left ventricular ejection fraction, MI myocardial infarction, 6MWT 6-minute walk test, COPD chronic 
obstructive pulmonary disease, ACEi angiotensin-converting-enzyme inhibitor, ARB angiotensin II receptor blocker, MRA mineralocorticoid 
receptor antagonist, eGFR estimated glomerular filtration rate, NGAL neutrophil gelatinase-associated lipocalin.
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Kaplan-Meier curves and the log-rank test on all the out-
comes showed no significant differences when patients 
were stratified according to BNP levels (Fig. 2).
NT-proBNP
All analyses were also performed using NT-proBNP lev-
els below and above 300 pg/ml; similar observations were 
made as with BNP. Results are presented in Supplementary 
Tables 1, 2 and 3 and Supplementary Fig. 1.
Discussion
The main finding of our study is that a group of patients 
exists who present and are admitted with heart failure symp-
toms and who, according to the current ESC guidelines, are 
not likely to be diagnosed with HFpEF because of a too 
Symptoms of heart failure
HFpEF patients in the COACH study were very symptom-
atic: patients reported on average four symptoms of heart 
failure. The most reported symptoms of heart failure were 
dyspnoea (96 %) and fatigue (88 %). Patients with low BNP 
levels did not differ in reported symptoms from patients 
with high BNP levels (Table 2).
Low BNP and predictive value
In the unadjusted Cox proportional hazard analyses no sig-
nificant prediction was observed for patients with low BNP 
levels regarding various outcome parameters (Table 3). 
Table 2 Quality of life and symptoms of patients with HFpEF enrolled in the COACH study: overall and stratified by BNP levels
Characteristics Total (n = 157) BNP < 100 pg/ml (n = 30) BNP ≥ 100 pg/ml (n = 127) p-value
Ladder of Life
Well-being 6 (2) 6 (2) 6 (2) 0.60
RAND-36
Physical functioning, mean (SD) 33 (25) 27 (21) 34 (26) 0.15
Social functioning, mean (SD) 58 (31) 61 (32) 57 (31) 0.51
Role limitation physical, mean (SD) 18 (33) 18 (32) 18 (33) 0.93
Role limitation emotional, mean (SD) 52 (46) 51 (47) 53 (46) 0.86
Mental health, mean (SD) 67 (21) 63 (21) 67 (21) 0.32
Bodily pain, mean (SD) 62 (34) 59 (35) 63 (33) 0.49
General health, mean (SD) 43 (18) 38 (19) 44 (18) 0.10
Health change, mean (SD) 27 (23) 26 (20) 27 (24) 0.84
Symptoms
Oedema, n (%) 108 (69 %) 25 (83 %) 83 (65 %) 0.06
Sleep disturbance, n (%) 105 (67 %) 18 (60 %) 87 (69 %) 0.37
Fatigue, n (%) 138 (88 %) 26 (87 %) 112 (88 %) 0.82
Dyspnoea, n (%) 150 (96 %) 30 (100 %) 120 (95 %) 0.19
Cough, n (%) 101 (64 %) 17 (57 %) 84 (66 %) 0.33
Loss of appetite, n (%) 76 (48 %) 10 (33 %) 66 (52 %) 0.07
Total number of symptoms (0–6) 4.3 (1.3) 4.2 (1.3) 4.3 (1.2) 0.57
BNP B-type natriuretic peptide.
Table 3 Cox proportional hazard analyses for different endpoints, 
comparing subjects with low BNP vs. high BNP
Endpoint Hazard ratio 95 % CI P-value
18 months
All-cause mortality &  
HF rehospitalisation
0.63 0.33–1.23 0.179
All-cause mortality 0.94 0.44–2.02 0.877
HF rehospitalisation 0.45 0.18–1.14 0.091
CV rehospitalisation 0.96 0.54–1.71 0.883
All-cause rehospitalisation 0.53 0.24–1.17 0.117
36 months
All-cause mortality 0.84 0.50–1.39 0.493
HF heart failure, CV cardiovascular.
Fig. 1 BNP levels stratified by the World Health Organization BMI 
classification scale in HFpEF patients
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of plasma BNP levels ≥ 100 pg/ml for diagnosing heart fail-
ure, in addition to the presence of symptoms of heart failure. 
As a result, patients with heart failure symptoms but with 
BNP levels < 100 pg/ml do not ‘officially’ have a diagno-
sis of heart failure, and physicians are advised to actively 
seek an alternative diagnosis. Therefore, it is expected that 
the prevalence of comorbidities among this patient popula-
tion will be higher than in patients with high BNP levels. A 
recent paper by Paulus et al. hypothesises that comorbidities 
may actually drive the myocardial dysfunction in HFpEF 
[15]. However, in our study we cannot clearly establish such 
a gradient between BNP levels and the number of comor-
bidities. The one exception was BMI. It has been published 
by others [16, 17] that BMI is a strong confounder of natri-
uretic peptides. Therefore, patients with a high BMI and 
low BNP levels may have ‘concealed’ heart failure, with 
disproportionately low BNP levels not properly reflecting 
left ventricular wall stress.
Usually, BNP directly reflects left ventricular wall stress, 
but apparently BMI interferes with this relationship. The 
one finding that validates the notion that lower BNP really 
associates with lower stress to the heart is our observation 
that also cTnI was lower in patients with lower BNP. Cardiac 
troponins are increasingly recognised as a major prognostic 
factor in heart failure [18]. Whether obesity has a relation-
ship with cTnI levels in acute heart failure remains unknown.
low BNP level. These patients suffer at least as much from 
their condition as patients who do meet the diagnostic crite-
ria of HFpEF. Further, they do not substantially differ from 
patients with HFpEF and BNP levels ≥ 100 pg/ml on a broad 
range of characteristics and heart failure symptoms. Most 
strikingly, the major difference was the higher BMI levels. 
Regarding different outcome parameters, we observed no 
differences between patients with low or high BNP levels, 
although we had limited power to ascertain this.
HFpEF and BNP levels
Although there is growing interest in HFpEF, there is limited 
understanding about the pathology of HFpEF. Natriuretic 
peptide levels have been advocated to aid the diagnosis 
of HFpEF. But our findings are in concert with emerging 
literature that natriuretic peptide testing in HFpEF is not 
straightforward. Yamamoto et al. have already stated that 
we should be cautious in using BNP alone in the diagnostic 
work-up, because BNP concentrations increase in normal, 
healthy older and/or female individuals, and in those with 
renal dysfunction and atrial fibrillation, and decrease in 
obese subjects [14].
So although BNP levels have powerful prognostic value, 
the diagnostic value of this biomarker is less clear. The ESC 
Heart Failure guidelines of 2008 introduced a requirement 
KEY MESSAGE  HFpEF patients with low BNP levels do not have a favorable outcome.
Fig. 2 Kaplan-Meier curves for various outcome parameters in patients with HFpEF, stratified by BNP level
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pharmacological treatment, these patients may likely benefit 
from exercise treatment, and referral to a rehabilitation centre 
would be advised [26]. Weight loss may paradoxically lead 
to an increase in BNP levels but a better performance score.
Strengths and limitations
This post-hoc study has several limitations. We defined 
HFpEF as an LVEF ≥ 40 % [27, 28], realising that the opti-
mal LVEF cut-off point is a matter of debate. The COACH 
study was performed before the era when echocardiography 
was a necessity for heart failure diagnostics and therefore 
the echocardiography data presented in this study cannot 
provide exact phenotyping of HFpEF patients. It could be 
suggested to measure BNP levels serially and use changes 
in BNP levels over time, instead of a single measurement, 
to diagnose HFpEF; unfortunately we could not address 
this issue. The sample size was small and these data should 
be regarded as hypothesis generating. However, due to the 
scarce data of HFpEF patients with low and high BNP, and 
as far as we are informed, our data are the first to address 
this subpopulation. Further, using our sample we were able 
to demonstrate significant differences which appear biologi-
cally plausible, especially the difference in BMI.
Another strength of the study is that we enrolled real-
life patients presenting with dyspnoea in specialised heart 
failure centres.
Conclusion
Patients with heart failure and a preserved ejection frac-
tion and plasma BNP levels < 100 pg/ml have the same 
clinical characteristics, an equal number and frequency of 
comorbidities, equally severe heart failure symptoms with 
impaired QoL, and the same poor outcome, when compared 
with patients with heart failure and a preserved ejection 
fraction and BNP levels ≥ 100 pg/ml. The major differ-
ence between the two groups was a higher BMI in HFpEF 
patients with low BNP. It should be considered to evaluate 
and treat patients with suspected HFpEF and BNP levels 
below the ESC guideline threshold in a comparable manner 
to that used for ‘official’ HFpEF patients.
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BNP cut-off point in HFpEF
In the Breathing Not Properly (BNP) Multinational Study, 
renal function correlated weakly with BNP levels, but more 
importantly it influenced the optimal BNP cut-off point 
[19]. Therefore, the ESC working group recommended an 
alternative cut-off point of 200–250 pg/ml to be considered 
in these patients [20].
Obesity also impacts BNP levels, even in subjects with-
out heart failure. In the Framingham Study, multivariable-
adjusted mean plasma BNP levels in lean (< 25 kg/m2), 
overweight (25–29.9 kg/m2), and obese (≥ 30 kg/m2) sub-
jects were 21.4, 15.5 and 12.7 pg/ml, respectively [21]. Not 
only obesity but also diabetes was associated with lower 
plasma BNP levels [21]. Ideally, these clinical aspects need 
to be taken into account when assessing a patient’s BNP 
level; however the attending clinician clearly favours a sin-
gle cut-off point.
Van Veldhuisen et al. [22] reported that although the BNP 
levels are lower in HFpEF patients compared with HFrEF 
patients, the prognosis in both patient groups is comparable 
given a certain BNP value. These findings were recently 
strengthened by the same observation by Kang et al. [23]. 
Whether natriuretic peptides are the best biomarkers to pre-
dict outcome in the low range is less well studied. Meijers et 
al. recently investigated whether and what biomarkers could 
assess low risk in patients with heart failure. Low levels of 
BNP or NT-proBNP did not strongly predict outcomes in 
these patients, whereas other biomarkers performed better 
and identified patients with a low risk for an adverse out-
come [24].
Clinical implementation: HFpEF with low versus high 
BNP
Our results show no apparent differences between the two 
patient groups in the frequency of comorbidities, except 
for BMI levels. As mentioned above, BNP levels decrease 
in obese patients [21]; thus, these patients may still suffer 
from HFpEF despite their (pseudo) lower BNP levels. These 
observations of the current study raise important questions 
regarding the use and interpretation of BNP levels as a bio-
marker for HFpEF.
The exact condition of ‘HFpEF’ patients with low BNP 
levels remains unclear, resulting in a dilemma for clinical 
practice when it comes to how to work up and how to treat 
these patients. Recently it was demonstrated that comorbidi-
ties might also influence the response to BNP-guided ther-
apy [25]. Our data suggest that the clinical work-up should 
probably be identical, as the clinical risk factor, the physi-
cal and mental unwell-being and the outcomes are almost 
identical. In particular, similar to patients with ‘real’ HFpEF, 
their physical functioning is low, and regardless of possible 
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